登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06383767,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically and/or cytologically confirmed HR+/HER2- breast cancer who had failed at least one line of systemic chemotherapy in metastatic settings;
入选标准第 3 条
Received chemotherapy, targeted therapy, immunotherapy, interventional therapy or other systemic anti-cancer therapie within 4 weeks before the first investigational product administration;
排除标准第 1 条
Toxicities from prior anti-tumor therapy not recovering to ≤ Grade 1;
排除标准第 2 条
Received major surgeries 4 weeks prior to the first dose of study treatment or planned to receive major surgeries during the study ;
排除标准第 3 条
Prior topoisomerase I inhibitor therapy, including antibody-drugconjugate(ADC) therapy, or prior TROP2 targeted therapy, or use of any investigational anti-cancer drug within 28 days or 5 half-lives before the first investigational product administration;
排除标准第 4 条
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1;
入选标准第 6 条
Patients with at least one measurable lesion per RECIST 1.1 criteria;
入选标准第 5 条
Patients with Primary CNS malignancy;or patients with other malignancies within 3 years prior to the first dose;
排除标准第 8 条
Human Immunodeficiency Virus (HIV) infection;
排除标准第 12 条
Female patients of childbearing potential and male patients with partners of childbearing potential who use effective medical contraception from the time of signing the informed consent form until 180 days after the last dose.
入选标准第 9 条
Pregnant or lactating women.
排除标准第 15 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06383767,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Individuals able to understand and give written informed consent. Males or females aged ≥ 18 years ; Histologically and/or cytologically confirmed HR+/HER2- breast cancer who had failed at least one line of systemic chemotherapy in metastatic settings; Patients who are eligible for a chemotherapy regimen in the control group; Patients with at least one measurable lesion per RECIST 1.1 criteria; Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1; Expected survival ≥ 12 weeks; Patients with adequate organ and bone marrow function; Female patients of childbearing potential and male patients with partners of childbearing potential who use effective medical contraception from the time of signing the informed consent form until 180 days after the last dose.排除标准:Exclusion Criteria:
Received chemotherapy, targeted therapy, immunotherapy, interventional therapy or other systemic anti-cancer therapie within 4 weeks before the first investigational product administration; Toxicities from prior anti-tumor therapy not recovering to ≤ Grade 1; Received major surgeries 4 weeks prior to the first dose of study treatment or planned to receive major surgeries during the study ; Prior topoisomerase I inhibitor therapy, including antibody-drugconjugate(ADC) therapy, or prior TROP2 targeted therapy, or use of any investigational anti-cancer drug within 28 days or 5 half-lives before the first investigational product administration; New thromboembolic events, intestinal obstruction, gastrointestinal bleeding or perforation within 6 months; Uncontrolled systemic bacterial, viral or fungal infections; Subjects with symptomatic or untreated CNS metastases, or those requiring ongoing treatment for CNS metastases; Patients with Primary CNS malignancy;or patients with other malignancies within 3 years prior to the first dose; Patients with uncontrollable systemic diseases; Patients with gastrointestinal diseases (such as chronic gastritis, chronic enteritis or gastric ulcers), or with a previous history of severe or chronic diarrhea; Subjects with clinically significant cardiovascular disease; Human Immunodeficiency Virus (HIV) infection; Active hepatitis B or hepatitis C; Known immediate or delayed hypersensitivity reaction to irinotecan or other camptocampin derivatives such as topotecan or to have had grade ≥3 gastrointestinal reactions associated with irinotecan, or allergies, or to any investigational drug or excipient ingredient; Pregnant or lactating women.
引自 ClinicalTrials.gov, NCT06383767, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06383767,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。